E26.02
Glucocorticoid-remediable aldosteronism
Clinical Classification Guidelines
Inclusion Terms
- Familial aldosteronism type I
Medical Intelligence & Overview
Glucocorticoid-remediable aldosteronism (GRA), also known as familial aldosteronism type I, is a rare inherited form of primary aldosteronism. It is characterized by excessive production of the hormone aldosterone, which can lead to issues like high blood pressure and imbalanced electrolytes. GRA is unique because it can often be managed effectively with glucocorticoid therapy, distinguishing it from other causes of elevated aldosterone levels.
Causes & Symptoms
Clinical Causes: Genetic mutation involving the fusion of specific genes regulating aldosterone production Inherited in an autosomal dominant pattern, meaning only one copy of the altered gene can cause the disorder The abnormal gene affects the adrenal glands, leading to overproduction of aldosterone that responds to adrenocorticoid regulation
Key Symptoms: High blood pressure (hypertension), often difficult to control Muscle weakness or fatigue due to electrolyte imbalances Frequent urination and excessive thirst Muscle cramps or spasms Headaches Unexplained or recurrent episodes of high blood pressure
Diagnostic & Treatment
Diagnosis Path: Diagnosis of GRA typically involves a combination of clinical evaluation and laboratory testing, including:
Treatment Protocols: The primary treatment for GRA involves controlling aldosterone production and managing blood pressure, often through:
Clinical Advice & FAQs
Billing Guidance
Is E26.02 a billable ICD-10 code?
Yes, E26.02 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E26.02?
Clinical documentation must specify the nature of Glucocorticoid-remediable aldosteronism and any associated comorbidities for accurate reporting.
Cite this Clinical Reference